Physician profile
John A Jarbath
NPI 1164481222
$1,352.84
in general payments reported to CMS, 2019-2025
10 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Foot Surgery provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $114 · 2022: $44.14 · 2023: $146 · 2024: $453 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $418.76 | 2022-2025 | Collagenase Santyl |
| Acera Surgical, INC. | $219.57 | 2024-2025 | Restrata Wound Matrix |
| Kerecis Limited | $171.89 | 2019-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Djo, LLC | $147.66 | 2019 | |
| Kci USA, INC. | $114.49 | 2019 | |
| Allergan, INC. | $114.16 | 2020 | |
| Integra Lifesciences Corporation | $95.64 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Paratek Pharmaceuticals, INC. | $30.15 | 2024 | Nuzyra |
| Abbvie INC. | $23.71 | 2023 | |
| Hydrofera LLC | $16.81 | 2023 | Hydrofera Blue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jarbath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.